Member Info for Elartu

Not enough radiologists, faster MRI scanning. Looks like the world needs some software to ease the burden on the radiological community and to keep pace with the faster MRI scanning throughput. Some company that solves that quandary could do very well for itself.

Might even be worth holding a demonstration / talk at The Royal College of Radiologists to let them know the kind of better than naked eye imaging that's available these days.
______________________________________________

"TexRAD detects and measures ‘tumour complexity’ in medical images and reveals more information than is readily visible to the naked eye."
______________________________________________

Royal College of Radiologists

Wednesday 12 September 2018 - 14:30 - 17:00

Textural analysis of CT and MR data
– ready for routine clinical use?

Dr Balaji Ganeshan, Senior Research
Associate, University College London
Hospitals NHS Foundation Trust
______________________________________________

Royal College of Radiologists

Wednesday 12 September 2018 - 14:30 - 17:00

Textural analysis of CT and MR data
– ready for routine clinical use?

Dr Balaji Ganeshan, Senior Research
Associate, University College London
Hospitals NHS Foundation Trust

https://www.rcr.ac.uk/sites/default/files/rcr18_programme_-_wednesday_12_september_2018.pdf

Links to Bob's news iyem

https://www.bbc.co.uk/news/health-45275071

https://www.bbc.co.uk/news/uk-scotland-45170707

https://www.bbc.co.uk/news/health-44871476

The false, wide spread allows the trades to appear in the wrong column. I can only assume the MM's don't wish to reveal buying interest at present. Why? It's usually because they have known buyers who wish to accumulate quietly without showing the spread moving upwards. They can get more shares cheaply with a bit of luck by hiding their interest.

TexRAD used in Endometrial Cancer trials.

Preoperative tumor texture analysis on MRI predicts high-risk disease and reduced survival in endometrial cancer: MRI Texture Analysis in Endometrial Cancer

In all, 180 patients with endometrial carcinoma were included from April 2009 to November 2013 and studied until January 2017. Field Strength/Sequences Preoperative pelvic MRI including contrast‐enhanced T1‐weighted (T1c), T2‐weighted, and diffusion‐weighted imaging at 1.5T. Assessment Tumor regions of interest (ROIs) were manually drawn on the slice displaying the largest cross‐sectional tumor area, using the proprietary research software TexRAD for analysis.

https://www.researchgate.net/publication/327005875_Preoperative_tumor_texture_analysis_on_MRI_predicts_high-risk_disease_and_reduced_survival_in_endometrial_cancer_MRI_Texture_Analysis_in_Endometrial_Cancer

TexRAD used on mice in Chinese anti-tumor cancer trials.

A novel approach to monitoring the efficacy of anti-tumor treatments in animal models: combining functional MRI and texture analysis.

https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4684-z

Conclusion

This study shows successful monitoring of the early phases of antiangiogenic therapy using multi-b-value DWI, DCE-MRI and texture analysis in a preclinical breast cancer model. Through the integration of multiple parameters, DWI, DCE and TexRad provide comprehensive and valuable information from biological characteristics to anatomic structures. More encouragingly, the prominent changes in key parameters before and after treatment both have good correlations and consistencies with histological results. The three imaging and analytic techniques reinforce each other and may potentially serve as non-invasive biomarkers for the guidance of treatment algorithms and in monitoring early responses to anti-angiogenesis therapy in future clinical trials.

Ethics approval and consent to participate

All animal experiments and relevant details were conducted in accordance with the approved guidelines and were approved by the committee on Animal Care and Use of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College.

If the TexRAD tech is rubbish as suggested what the hell chance does Stone Checker have of working? If, as indicated on the Stone Checker website the software they are using is only "based on the TexRAD algorithm" does that mean the underlying software has been modified and now requires new CE Mark and FDA approvals before it can be released for use? If Stone Checker cannot be released because of TexRAD modifications does it even have the necessary worldwide patents needed before clinical trails take place?

As the TexRAD software is 100% owned by Feedback plc does Stone Checker even have written authority from Feedback to modify this software?

CT texture analysis of pancreatic cancer

Sixty patients with unresectable pancreatic cancers at presentation were enrolled for post-processing with CTTA using commercially available software (TexRAD Ltd, Cambridge, UK).

https://www.springermedizin.de/ct-texture-analysis-of-pancreatic-cancer/16041124

Error on time - should be 32:45.

https://audioboom.com/posts/6975285-the-weekend-podcast

Short chat on Feedback starting around 52:45.

https://audioboom.com/posts/6975285-the-weekend-podcast

Morning Horsford, the group did, indeed, represent a number of top medical imaging companies. I suppose that was the main reason I ended up disappointed at what I watched. Not a single member on stage truly sold their product well that day. When you know you only have 5-10 minutes to get the unique properties of your product across to the audience you should have practised your speech until it was word perfect. One bloke was reading his off his mobile phone for god's sake.

I used to give speeches from time to time and whilst never an expert I had picked up books on the subject to help me avoid some of the pitfalls of public speaking. I don't believe any of those guys had done the same.

I can't remember all the rules nowadays but some were:

1. Know the level of the audience you will be speaking to. Pitch the level of the talk to suit the audience.
2. Ensure you cover their particular interests. (Tell radiologists how you can save them time and money).

For a 10 minute chat,

3. Tell them what you are going to tell them - intro (1 minute).
4. Tell them (and make sure you stress the unique selling points - main sales pitch) (8 minutes)
5. Tell them what you told them - sum it all up (1 minute)

During the talk.

6. Have some water available in case you get nervous and dry up.
7. Stand up, move around, show enthusiasm, use visuals to break up the talk. Talk slowly, don't jabber.
8. Make eye contact with audience in general - don't fixate on one audience member.
9. Stress the important stuff - in TexRAD's case - it sees more than any human eye can.

10. Thank audience for listening and open up a Q&A session.

I wish I'd seen more of all that in the video. BG still did better than most others though.

Here's half a dozen or so very bright guys showing you how NOT to run a discussion group / Q&A session.

Balaji Ganeshan starts talking about TexRAD around the 15 minute mark so you might find that interesting. However, I get the feeling there are a few dinosaur radiologists in the audience who didn't grasp the fact that TexRAD can pinpoint features that cannot be seen by the human eye... or perhaps they just didn't want to acknowledge that (even to themselves).

https://vimeo.com/282859358

Bob, my take is this. Feedback is a tiddler of a share in a large watery expanse of small, medium, large and enormous share sea beasts. As such it warrants almost no time by humans at the market makers. They probably leave the running of it to software algorithms 99.9% of the time. When an RNS comes through they scan it for positive vs. negative words / phrases and adjust the share price accordingly and quickly. When trades come through after the RNS they check the number of buy to sell shares and apply a ratio. If the ratio isn't within the one expected by the algorithm then the price moves. You see it all the time when a large trade appears the price goes up / down instantly in most cases. This is not done by a super fast human at a keyboard, it is done by artificial intelligence (AI). So as per yesterday, the RNS comes out and positive words outweigh negative and the AI moves the price upwards but the the sell on news guys started to sell as the bell went and there was the tiniest of dips as the software made an adjustment for it. By lunchtime that tiny dip in price enticed buyers and they (or their AI software) jumped in looking for a bit of a bargain and the price moved up properly for the first time on trading traffic that day. The AI pushed up and up until sellers appeared to allow MM books to seek equilibrium. And so it goes, the AI works according to rules and is very adept at getting balance most days. It's the days when they can't balance for whatever reason when the roller coaster starts up and the share price adjusts drastically.

On the 15th & 16th Mike Hayball sold 650k shares and we had the late 985k buy - I doubt one would have happened without the other. We need to find a way for long term holders like Mike and Trevor to stop self-sabotaging the share price for it to really climb.

With Trevor we knew he was pushing the price down through malice and I commend the BoD for having the fortitude to not issue good news until he was done and dusted. With Mike they may very well have to do that all over again but this time if Mike wants out then perhaps some orderly disposal can be arranged.

The insane spread is almost certainly down to unbalanced MM books. When books are balanced prices are closer as each firm sits top / bottom of the price tree only long enough to do a bit of trading whilst keeping their books balanced. Snag or dispose of a few shares then move over and let someone else sit top of the tree.

My guess right now is we have at least one, and maybe two, firms whose books are unbalanced and they are trying to tidy themselves up before the quarterly inspection.

It's all a bit frustrating for us little guys and we will have to wait it out until others release / take up shares and allow all the MM's to have balanced books. Once that happens the share price should flow steadily upwards with each exciting RNS.

P.S. I wouldn't be surprised if the same AI software doesn't also trawl these pages too

And, unless I am much mistaken, the game is...

"Siemens (one of the market leaders for scanning machines) are now starting to bundle TexRAD software into their equipment sales."

El was having his evening stroll. Yes, I don't see how that can be anything other than a buy trade. Very cultural of you Horsford, slipping a word conceived by Shakespeare into your post.

"I see you stand like greyhounds in the slips,
Straining upon the start. The game's afoot:
Follow your spirit, and upon this charge
Cry 'God for Harry, England, and Saint George!'

And liberally used by Sherlock Holmes afterwards.

"Come Watson, come! The game is afoot. Not a word! Into your clothes and come!"

Hi Horsford, I meant director as in being on the Board of Directors but, yes, I get your point and Mike is obviously a clever bloke so his selling is a bit of a concern. On the other hand, he doesn't hold the share numbers that Trevor Brown had so even if he sells out completely it shouldn't take too long. I'm just finding it a bit frustrating when so much appears to be going well. If Alastair did that podcast as an antidote to today's RNS then he's being to wily for his own good.

Mike Hayball isn't a director, nevertheless his selling is annoying.

https://www.investegate.co.uk/feedback-plc--fdbk-/rns/director-pdmr-shareholding/201808171402001943Y/

The buyers have been late to the game today but they are out in force in the last 20 minutes.

It's just like watching a (rare) QPR comeback.

Preoperative tumor texture analysis on MRI predicts high‐risk disease and reduced survival in endometrial cancer

https://onlinelibrary.wiley.com/doi/abs/10.1002/jmri.26184

One of the authors - Balaji Ganeshan PhD.
Analysis software - TexRAD.

First new research paper I've found in awhile.

Now 15k at 2.197p.